Uncoupling tumor immunogenicity from cell death with platinum(Ⅳ)-antibody conjugates
摘要
Platinum drugs remain mainstays for solid tumors,but systemic toxicity and difficult dose finding in immunotherapy combinations limit their use.We engineer platinum(Ⅳ)-antibody conjugates[Pt-ADCs(platinum-based antibody-drug conjugates)]that confine a'metal immune effect'to tumors while reducing off-tumor exposure.Site-specific glycoengineering installs redox-responsive Pt(Ⅳ)prodrugs at defined drug-to-antibody ratios,yielding homogeneous conjugates.Mechanistic profiling shows that cisplatin-derived,but not oxaliplatin-derived,payloads undergo efficient reductive activation in the tumor milieu;cinnamate-capped variants optimize serum stability,intratumoral release,and immunostimulatory signaling.In syngeneic models,Pt-ADCs deliver a low dose of cinnamate-capped Pt to upregulate major histocompatibility complex class Ⅰ on tumor cells,expand tumor-reactive T-cell receptor clonotypes,and synergize with PD-1 blockade to suppress tumor growth,with minimal systemic toxicity.These findings position Pt-ADCs as a detoxified,immunogenic modality that uncouples immunogenic priming from high-dose cytotoxicity and offers a tractable path to rational dosing in chemo-immunotherapy combinations.
年,卷(期):
2026, 13(10)
机标分类号:
TP393.05
R96
R738
在线出版日期:
2026年7月22日